Skip to content
value.today

Ambu A/S: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

The market value here is from Aug 1, 2026, more than 60 days ago: no market-data feed is connected for this exchange yet, so read the comparisons with today's price with that in mind.

Cash-flow value

Fewer than two of the last three years have both cash from operations and capital spending on file.

Price to bookPrice to book of Medical Instruments: $1.8 B to $6.0 B, median $4.1 B$0 M$1.6 B$3.3 B$4.9 B$6.5 BMarket value $3.2 B

Your own DCF model

A full discounted-cash-flow model of Ambu A/S, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Medical Instruments

Multiples of its companies with a market value at most 60 days old, times Ambu A/S's own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Ambu A/SApplied toValue (25th to 75th)Companies
Price to book2.0× / 4.4× / 6.6×3.4×book equity $914 M$1.8 B to $6.0 B23

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Jun 30, 2026——————ESEF annual report
FY2024to Jun 30, 2025——————ESEF annual report

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $3.2 B on Aug 1, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.